Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kidney transplant patients battling BK virus

NCT ID NCT04542733

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times

Summary

This study looks at two drug combinations to treat BK virus infection in kidney transplant recipients. BK virus can cause the new kidney to fail. The trial compares everolimus with a lower dose of tacrolimus versus a lower dose of tacrolimus plus leflunomide in 50 adults whose virus did not clear after reducing their usual anti-rejection medicines. The main goal is to see which combination lowers the virus level more over six months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • King Chulalongkorn Memorial Hospital

    Bangkok, Bangkok, 10330, Thailand

Conditions

The condition(s) this trial relates to.

BK-virus nephropathy renal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.